

RESEARCH ARTICLE

Circumcision Status and Risk of HIV Acquisition during Heterosexual Intercourse for Both Males and Females: A Meta-Analysis

Jun hao LEI¹*, Liang ren LIU¹*, Qiang WEI¹*, Shi bing YAN²*, Lu YANG¹, Tu run SONG¹, Hai chao YUAN¹, Xiao LV¹, Ping HAN¹*

1 Department of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, China,

2 Department of Urology, Dujiangyan Medical Center/ the affiliated hospital of Chengdu University, Dujiangyan, China

* These authors contributed equally to this work.

* weiqiang393@126.com (QW); 14258353@qq.com (PH)



OPEN ACCESS

Citation: LEI Jh, LIU Lr, WEI Q, YAN Sb, YANG L, SONG Tr, et al. (2015) Circumcision Status and Risk of HIV Acquisition during Heterosexual Intercourse for Both Males and Females: A Meta-Analysis. PLoS ONE 10(5): e0125436. doi:10.1371/journal.pone.0125436

Academic Editor: Julian W. Tang, Alberta Provincial Laboratory for Public Health/ University of Alberta, CANADA

Received: June 30, 2014

Accepted: March 23, 2015

Published: May 5, 2015

Copyright: © 2015 LEI et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper and its Supporting Information files.

Funding: The authors have no support or funding to report.

Competing Interests: The authors have declared that no competing interests exist.

Abstract

In this study, we evaluated if male circumcision was associated with lower HIV acquisition for HIV (–) males and HIV (–) females during normal sexual behavior. We performed a systematic literature search of PubMed, EMBASE, and Cochrane Central Register of Controlled Trials (CENTRAL) databases to identify studies that compared HIV acquisition for the circumcised and uncircumcised groups. The reference lists of the included and excluded studies were also screened. Fifteen studies (4 RCTs and 11 prospective cohort studies) were included, and the related data were extracted and analyzed in a meta-analysis. Our study revealed strong evidence that male circumcision was associated with reduced HIV acquisition for HIV(–) males during sexual intercourse with females [pooled adjusted risk ratio (RR): 0.30, 95% CI 0.24–0.38, $P < 0.00001$] and provided a 70% protective effect. In contrast, no difference was detected in HIV acquisition for HIV (–) females between the circumcised and uncircumcised groups (pooled adjusted RR after sensitivity analysis: 0.68, 95%CI 0.40–1.15, $P = 0.15$). In conclusion, male circumcision could significantly protect males but not females from HIV acquisition at the population level. Male circumcision may serve as an additional approach toward HIV control, in conjunction with other strategies such as HIV counseling and testing, condom promotion, and so on.

Introduction

The relationship between circumcision status and the prevention of sexually transmitted diseases (STDs) was described initially by Hutchinson almost 150 years ago [1], and its potential protective effect for HIV acquisition was reported in 1986 [2]. Recently, many prospective studies, particularly three large RCTs, showed that male circumcision provided a protective effect for males [3–5]. A systematic review summarized the three trials published in the Cochrane Library in 2013 and reported a pooled RR of 0.46 at 21 and 24 months (95% CI:

0.34–0.62, $P = 0.0002$) [6]. However, the evidence is inadequate. Many longitudinal studies concerning the relationship between circumcision status of HIV (−) males and HIV acquisition from their female partners should also be considered [7–12]. On the other hand, the available evidence concerning the relationship between male circumcision status and HIV acquisition for their HIV (−) female partners is still inconsistent [13–22].

In the current study, we included RCTs and prospective cohort studies to examine whether male circumcision provided a protective effect for males themselves and for their female partners.

Methods

Inclusion Criteria and Search Strategy

Studies that met all the following criteria were included: randomized controlled trial or cohort study: a) in which sexual activity was limited to heterosexuality, b) with male circumcision as a study variable or an exposure variable and c) that reported quantitative data reflecting the association of circumcision status and HIV acquisition for either males or females.

We searched for such studies in the PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library. PubMed was searched using the following terms: Circumcision, Male [MeSH] or Circumcision [tw] or male circumcision [tw] or circumcise [tw] or Shang Ring [tw] and HIV Infections [MeSH] or HIV [MeSH] or human immunodeficiency virus [tw] or hiv infect [tw] or AIDS [tw] or Acquired Immune Deficiency Syndrome [MeSH] or STD [tw] or sexually transmitted diseases [MeSH]. The other two databases were searched using similar keywords according to their search rules. The reference lists of the included studies, other reviews, and related articles not identified by our electronic searches were also screened for additional possible studies. HIV (+) individuals were identified after testing positive for two types of enzymes in immunoassays of venous blood samples. Discordant enzyme immunoassay results were confirmed by western blot [19]. To minimize the clinical and methodological heterogeneity, we only included RCTs or cohort studies.

Data Extractions, Quality Assessment and Data Analysis

LY and PH performed study selection and data extraction independently. The items extracted from the 15 eligible studies are shown in Table 1. The effect measures for unadjusted and adjusted RRs were also extracted. The adjusted RRs were preferentially used for the meta-analysis; otherwise, the unadjusted RRs were used. Any disagreements were solved by discussion within the study group.

According to the recommendations of the Cochrane collaboration, the quality of the 15 studies was assessed based on the study design, conduct, and analysis [23]. Different assessment items were used for RCTs and cohort studies. We evaluated each study using a three-point scale: yes (low risk of bias), no (high risk of bias) and unclear. The heterogeneity of effects between studies was assessed using a χ^2 test with a significance level of $P < 0.1$. Possible heterogeneity was quantified using the I^2 statistic ($30\% < I^2 < 75\%$, moderate heterogeneity; $I^2 > 75\%$, considerable heterogeneity) [24]. Pooled risk ratio(RR) with 95% confidence intervals (CI) was calculated using Mantel-Haenszel random effects model to estimate the effect of male circumcision when $I^2 > 75\%$; otherwise, a fixed effect model was used. Publication bias was assessed using funnel plots [25]. All analyses were performed using Review Manager 5.0.

Table 1. Summary table of correlation of male circumcision status and HIV acquisition.

Study/ study design	sites	population	size analyzed in cir./unc. group	follow up duration	proportion with circumcised male	HIV(+) rate in circumcised group	HIV(+) rate in uncircumcised group	Unadjusted RR# (95% CI&)	Adjusted RR(95% CI)
Studies concerning HIV acquisition from female to male									
Auvert2005 /RCT	South Africa	male of general population	1546/1582	21mons	49%	0.85 per 100 pyo*	2.1 per 100 pyo	0.40 (0.24–0.68)	0.39 (0.23–0.66)○
Bailey2007 /RCT	Kisumu, Kenya	HIV(-) male	1391/1393	24mons	50%	2.1% (1.2–3.0)	4.2% (3.0–5.4)	0.47 (0.28–0.78)	0.41 (0.24–0.70)○
Gray2007 /RCT	Rakai, Uganda	HIV(-) male	2474/2522	24mons	50%	0.66 per 100 pyo	1.33 per 100 pyo	0.49 (0.28–0.84)	0.49 (0.29–0.81)⊕
Cameron1989 /P. Cohort	Nairobi, Kenya	STD clinic visitors	214/79	No	73%	No	No	0.10 (0.04–0.22)	0.12 (0.04–0.33)♂
Lavreys1999 /P. Cohort	Mombasa, Kenya	HIV(-) male	651/95	20mons	13%	2.50 per 100 pyo	1.8 per 100 pyo	0.42 (0.22–0.81)	No
Wawer1999 /P. Cohort	Rakai, Uganda	Subgroup1 (S1): HIV(-) male	409/1635	20mons	20%	1.40 per 100 pyo	No	0.97 (0.36–2.25)	No
		No	346/1961	20mons	15%	0.70 per 100 pyo	No	0.45 (0.09–1.40)	No
Ronald2000 /P. Cohort	Rakai, Uganda	HIV(-) male	908/4608	49mons	16%	1.10 per 100 pyo	1.8 per 100 pyo	0.61 (0.37–0.97)	0.53 (0.33–0.87)○
Reynolds2004 /P. Cohort	Pune, India	HIV(-) male	191/2107	12mons	8%	0.70 per 100 pyo	5.50 per 100 pyo	0.13 (0.02–0.47)	0.15 (0.04–0.62)♀
Gray2012 /P. Cohort	Rakai, Uganda	HIV(-) male	3198/402	4.79years	89%	0.50 per 100 pyo	1.93per 100 pyo	0.27 (0.16–0.44)	0.27 (0.16–0.45)☆
Studies concerning HIV acquisition from male to female									
Wawer2009 /RCT	Rakai, Uganda	Female with HIV(+) partners	92/67	24mons	58%	18% (17/92)	12% (8/67)	1.58 (0.68–3.66)	1.49 (0.62–3.57)※
Kapiga1998 /P. Cohort	Dar es Salaam, Tanzania	Family planning clinic visitors	1022/22	34mons	98%	2.60 per 100 pyo	9.20 per 100 pyo	0.28 (0.09–0.89)	0.29 (0.09–0.97)▽
Reynolds2006 /P. Cohort	Rakai, Uganda	Couples with HIV(+) males	No	No	13%	6.60 per 100 pyo	10.3 per 100 pyo	0.67 (0.45–1.00)	No
Turner2007 /P. Cohort	Zimbabwe	Family planning clinic visitors /STD clinic visitors /sex workers	989/3249	24mons	30%	2.03 per 100 pyo	2.96 per 100 pyo	0.69 (0.48–0.99)	0.78 (0.53–1.14)○

(Continued)

Table 1. (Continued)

Study/ study design	sites	population	size analyzed in cir./unc. group	follow up duration	proportion with circumcised male	HIV(+) rate in circumcised group	HIV(+) rate in uncircumcised group	Unadjusted RR# (95% CI&)	Adjusted RR(95% CI)
Baeten2010 /P. Cohort	14 sites in east/ southern Africa	Couples with HIV(+) males	374/722	24mons	34%	2.72 per 100 pyo	4.38 per 100 pyo	0.62 (0.35–1.10)	0.56 (0.30–1.05)§

RCT: randomised controlled trial. P. Cohort: prospective cohort study.

*Person-years of observation.

#Risk ratio is incidence rate (or hazard) ratios for RCT and Cohort shown.

&Confidence interval.

◊Hazard ratio adjusted for sexual behaviour that increased slightly in the intervention group, condom use, and health-seeking behavior.

Hazard ratio adjusted for non-adherence to treatment and excluding four men found to be seropositive at enrolment.

⊕Rate ratio adjusted for age, marital status, and sexual risk behaviours at enrolment.

♂Adjusting factors were not achieved.

◊Rate ratio adjusted for age, marital status, sexual partners in past year, sex for money, condom use and syphilis.

♀Rate ratio adjusted for Hindu/non-Hindu religion, level of education, living with family; and time-dependent covariates: calendar year, age group, marital status, multiple sex partners, number of female sex-worker partners (0, 1, 2–9, or 10+), condom use, tattoos, and medical injections.

☆Hazard Ratio adjusted for sociodemographic characteristics at the last trial visit and time-dependent sexual behaviors during posttrial follow up.

×Hazard ratio adjusted for age and condom usage.

▽Rate ratio adjusted for age, marital status, gonorrhea/candidiasis at baseline, number of sexual partners and alcohol consumption during the follow-up period.

◊Hazard ratio adjusted for age, age at coital debut, contraceptive method, husband's employment status, education, number of partners in past 3 months, and a product-interaction term between time and number of partners in past 3 months.

§Hazard ratio adjusted for male partner HIV-1 plasma viral load and censored at male partner antiretroviral therapy initiation.

№Dates were not available.

doi:10.1371/journal.pone.0125436.t001

Results

Search results

A total of 4750 citations were identified ([S1 Fig](#)). Following the patients, intervention, comparison, and outcome (PICO) principle recommend by the Cochrane Collaboration, 4736 were excluded after reviewing the title, abstract, and eventually the full text. Finally, 14 articles (15 studies) were included for meta-analyses. Ten of the 15 studies assessed HIV acquisition for males and 5 analyzed HIV acquisition for females.

Characteristics of the included studies

One study was a conference abstract [18], and the others were published between 1989 and 2012 ([Table 1](#)) [3–11, 19–22]. Of the 15 studies, 4 were RCTs, and the others were prospective cohort studies. The quality evaluation for each study is shown in [S2 Fig](#).

HIV transmission from females to males. Ten studies (three RCTs and seven prospective cohort studies) included 27712 males (circumcised/uncircumcised, 11328/16384). Although Auvert et al enrolled males from the general population initially, only the HIV (−) subpopulation were used for analysis [3]. The subjects in the study by Cameron et al were visitors to an STD clinic; we used only data from the HIV (−) subgroup in the analyses [7]. The remaining eight studies included only HIV (−) males.

HIV transmission from males to females. Five studies were related, including one RCT and four prospective cohort studies. Turner et al enrolled females from family planning clinics, STD clinics and sex workers (circumcised/uncircumcised partners, 989/3249) [21], whereas Kapiga et al enrolled only visitors to family planning clinics (circumcised/uncircumcised partners, 1022/22) [20]. Both studies investigated the HIV status of male partners based on the reports of females [20, 21]. Their HIV status were (–) when included, but the HIV status of their male partners was not available. The other three studies contained serodiscordant heterosexual couples, with HIV (–) females and HIV (+) male partners [18, 19, 22].

Outcome measures

The basic characteristics of all the included studies are shown in [Table 1](#). Eleven authors explicitly calculated the unadjusted and adjusted RRs, whereas four studies (Lavreys et al [17], Wawer et al (s1, s2) [22], and Reynolds et al [20]) only presented the unadjusted RR [8, 11, 19].

HIV transmission from females to males. The results of 9 studies assessing HIV transmission from females to males consistently reported a protective effect of circumcision for males themselves. Our pooled analysis for the unadjusted RR was 0.26 (95% CI 0.21–0.32, $P < 0.00001$), and the adjusted RR was 0.30 (95% CI 0.24–0.38, $P < 0.00001$) ([S3 Fig](#)). The results of sensitivity analysis of the pooled adjusted RR after eliminating 3 studies (Cameron et al, Lavreys et al, and Reynolds et al) were 0.40 (95% CI 0.31–0.53, $P < 0.00001$) [7, 8, 11]. When only 3 RCT studies were considered, the adjusted RR was 0.43 (95% CI 0.29–0.63, $P < 0.0001$).

HIV transmission from males to females. The results of the 5 studies assessing HIV transmission from males to females were inconsistent. One RCT showed an insignificant adverse effect, whereas four prospective cohort studies reported a protective effect. The summary unadjusted RR was 0.59 (95%CI 0.40–0.88, $P = 0.01$), and the adjusted RR was 0.55 (95% CI 0.33–0.93, $P = 0.03$) with a moderate heterogeneity ([S4 Fig](#)). The sensibility analysis result of the pooled adjusted RR was 0.68 (95% CI 0.40–1.15, $P = 0.15$) after excluding studies by Kapiga and Turner [20, 21].

Discussion

HIV acquisition for males

Overall, our pooled analysis demonstrated that circumcision provided a 70% protective effect for HIV acquisition. These results were consistent with a previous meta-analysis performed in 2000 [26]. Most studies included in the meta-analysis were cross-sectional or case-controlled studies, without RCTs. They reported a 58% protective effect (adjusted RR: 0.42, 95% CI 0.34–0.54). Here, we only included RCTs or prospective cohort studies. Then, focusing on the 3 excellent RCT studies, they were all stopped early because of ethical concerns for the uncircumcised group [3–5]. Nevertheless, their available data still showed a significant reduction in the incidence of HIV in circumcised males. The study published by Gray et al in 2012 was a prospective post-trial surveillance cohort study that enrolled the study population of a previous RCT performed by the same group in 2007 [5, 12]. This cohort study was performed as an as-treated analysis during a 4.79-year post-trial surveillance, and males were classified by their actual circumcision status. This study provided definitive evidence for the long-term protective effect of male circumcision.

We performed sensitivity analysis by eliminating the studies by Cameron et al, Lavreys et al, and Reynolds et al [7, 8, 11]. The studies by Cameron et al and Lavreys et al both included relatively small population size. Secondly, the full text of the study by Cameron et al hadn't been acquired. So, it was not available to extract some important information, e.g., follow up

duration and HIV (+) rate in both groups. The absence of these data worried us that the duration might be too short to unfold the effect of circumcision. In addition, baseline information in the study by Lavreys et al was not comparable in terms of history of condom use, the use of cigarettes, age, and so on; baseline information on genital ulcers, marital status, and religion differed in the study by Reynolds et al. The conclusion from the newly adjusted RR data was consistent with the previous pooled RR, with a high homogeneity ($\chi^2 = 4.66$, $I^2 = 0\%$). This result strengthened our confidence that male circumcision reduced HIV acquisition for circumcised males.

Some of the mechanism underlying the protective effect of circumcision may be related to mucosal immunity and the barrier function of the epithelium. First, males may be easily infected via the inner foreskin and frenulum, which contain large numbers of HIV-targeting Langerhans cells [27]. Their adsorptive capacity is 9-times higher than that of the outer foreskin [28]. In addition, tissue studies have shown that the inner foreskin and frenulum are less keratinized, and that their horny layer is thinner and could easily be scraped. The thinner anatomical barrier between the vaginal secretions at the inner foreskin and the Langerhans cells allow for a more effective penetration of the virus [29]. Male circumcision could sharply decrease the transmission area by removing most of the inner foreskin. Circumcision also reduces the risk of other STDs, which can secondarily reduce the risk of HIV acquisition for males [34–36].

HIV acquisition for females

Based on the sensibility analysis result ($P = 0.15$), it showed that male circumcision did not provided significant protective effect for their female partners. However, an important issue of the HIV status of women's partners should be raised.

The 2 cohort studies were conducted among HIV negative women but the HIV status of their partners was not known [20, 21]. However, the studies by the other 3 were conducted in discordant couples. In these studies, HIV incidence was compared in women with an HIV (+) partner who was circumcised with women with an HIV (+) partner who was not circumcised. In other words, the studies in discordant couples should not be mixed up with the studies by Kapiga and Turner because they measure different things. The sensibility analysis result of new pooled RR after excluding the studies by Kapiga and Turner was 0.68 (95% CI 0.40–1.15, $P = 0.15$) and showed a high homogeneity ($\chi^2 = 1.02$, $I^2 = 0\%$) [20, 21]. In conclusion, the protective effect of male circumcision to their female partners did not exist based on the current evidence. Our conclusion was consistent with the previous meta-analysis performed by Weiss et al in 2009 [30]. However, they maxed up the different populations as we discussed above; besides, we did not include any cross-sectional studies for the fear of their inherent inferiority to unfold the causality.

After reviewing all the relevant studies included, some issue must be raised. The RCT trial performed by Wawer et al was stopped early by the Data Safety and Management Board for reasons of futility [19]. Consequently, only 92 and 67 serodiscordant couples had been enrolled in to the circumcised and uncircumcised groups, respectively, significantly decreasing the power of the study. The study concluded that circumcision had an adverse effect on HIV acquisition, with an adjusted RR of 1.49 (95% CI 0.62–3.57). A rigorous RCT conducted by Kigozi et al found that the risk of HIV transmission from circumcised HIV (+) males to female partners increased if intercourse occurred before complete wound healing [31]. Consistent with this, Wawer et al demonstrated that, in couples resuming intercourse more than 5 days before male partner's wound was certified as completely healed and within the 5 days before or any time after certified wound healing, 27.8% (5/18) and 9.5% (6/63) seroconversions were

observed ($P = 0.06$), respectively. Therefore, care providers should remind their patients to delay resuming intercourse or use condoms.

The effect of male circumcision on female HIV acquisition may depend on HIV penetration directly from the inner foreskin or frenulum, as well as factors that affect HIV transmission such as genital ulceration and HPV [32, 33]. Published RCTs have reported that male circumcision is associated with a lower incidence of HPV, HSV-2, and syphilis in the circumcised male themselves [34–36]. For example, after a HIV (+) male was circumcised, both the transmission area and the incidence of HPV infection, decreased. Subsequently, his female partner benefited from a reduced transmission area and rate of HPV acquisition, which may lower her risk of HIV acquisition. Unfortunately, our study did not identify any evidence to support this protective effect. Therefore, more convincing data from multicenter RCTs, particularly among sero-discordant couples with HIV (+) males, may reveal a protective effect.

Limitations

Our study has limitations that must be discussed. All analyses were based on extracted rather than individual patient data; therefore, the results must be interpreted cautiously. Second, publication bias is an additional inherent limitation, since the funnel plot showed evidence of publication bias. Only 2 of 10 studies concerning HIV acquisition for male did not report a protective effect, which may overestimate the effect of male circumcision.

Conclusions

In conclusion, our results provide strong evidence that male circumcision was effective for reducing HIV acquisition for males. Consequently, WHO and UNAIDS have recommended male circumcision as an important part of a comprehensive HIV prevention package among males [37, 38]. However, no protective effect was found for the female sexual partners of circumcised males. Finally, at high HIV prevalence area, circumcision should be considered as a part of HIV prevention strategies, which should also include HIV counseling and testing, condom promotion, changing sexual habits, and so on. The benefit would then be expanded to its fullest potential for both males and females.

Supporting Information

S1 PRISMA Checklist.

(DOC)

S1 Fig. Flow diagram for included and excluded articles.

(TIF)

S2 Fig. Quality evaluation of included studies. *there are 4 RCT. The 6 items on the left side with “?” were used for evaluation of RCT study, and the others 8 items on the right side were used for evaluation of Cohort study.

(TIF)

S3 Fig. Forest plot of adjusted RR of HIV acquisition from female to male.

(TIF)

S4 Fig. Forest plot of adjusted RR of HIV acquisition from male to female.

(TIF)

Author Contributions

Conceived and designed the experiments: JHL LRL. Performed the experiments: LY PH SBY. Analyzed the data: XL SBY HCY. Contributed reagents/materials/analysis tools: TRS SBY. Wrote the paper: JHL LRL. Commented in detail on the drafts and approved the final version: TRS QW SBY.

References

1. Hutchinson J. On the influence of circumcision in preventing syphilis. *Med Times Gaz* 1855; 2: 542–3.
2. Fink A. A possible explanation for heterosexual male infection with AIDS. *N Engl J Med* 1986; 314: 1167.
3. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. *PLoS Med* 2005; 2: 298.
4. Bailey RC, Moses S, Parker CB, Agot K, Maclean I, Krieger JN, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. *Lancet* 2007; 369: 643–56. PMID: [17321310](#)
5. Gray RH, Kigozi G, Serwadda D, Makumbi F, Watya S, Nalugoda F, et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. *Lancet* 2007; 369: 657–66. PMID: [17321311](#)
6. Siegfried N, Muller M, Volmink J, Volmink J. Male circumcision for prevention of heterosexual acquisition of HIV in men. *Cochrane Database Syst Rev* 2013; 5:CD003362.
7. Cameron DW, Simonsen JN, D'Costa LJ, Ronald AR, Maitha GM, Gakinya MN, et al. Female to male transmission of human immunodeficiency virus type 1: risk factors for seroconversion in men. *Lancet* 1989; 2: 403–7. PMID: [2569597](#)
8. Lavreys L, Rakwar JP, Thompson ML, Jackson DJ, Mandaliya K, Chohan BH, et al. Effect of Circumcision on Incidence of Human Immunodeficiency Virus Type 1 and Other Sexually Transmitted Diseases: A Prospective Cohort Study of Trucking Company Employees in Kenya. *The Journal of Infectious Diseases* 1999; 180: 330–6. PMID: [10395846](#)
9. Wawer MJ, Sewankambo NK, Serwadda D, Quinn TC, Paxton LA, Kiwanuka N, et al. Control of sexually transmitted diseases for AIDS prevention in Uganda: a randomised community trial. *Rakai Project Study Group*. *Lancet* 1999; 353: 525–535. PMID: [10028980](#)
10. Ronald HG, Noah K, Thomas CQ, Sewankambo NK, Serwadda D, Mangen FW, et al. Male Circumcision and HIV acquisition and transmission: cohort studies in Rakai, Uganda. *AIDS* 2000; 14: 2371–81. PMID: [11089626](#)
11. Reynolds SJ, Shepherd ME, Risbud AR, Gangakhedkar RR, Brookmeyer RS, Divekar AD, et al. Male circumcision and risk of HIV-1 and other sexually transmitted infections in India. *Lancet* 2004; 363: 1039–40. PMID: [15051285](#)
12. Gray R, Kigozi G, Kong XR, Ssempejja V, Makumbi F, Watya S, et al. The effectiveness of male circumcision for HIV prevention and effects on risk behaviors in a posttrial follow-up study. *AIDS* 2012; 26: 609–615. doi: [10.1097/QAD.0b013e3283504a3f](#) PMID: [22210632](#)
13. Hunter DJ, Maggwa BN, Mati JK, Tukei PM, Mbugua S. Sexual behavior, sexually transmitted diseases, male circumcision and risk of HIV infection among women in Nairobi, Kenya. *AIDS* 1994; 8: 93–99.
14. Malamba SS, Mermin JH, Bunnell R, Mubangizi J, Kalule J, Marum E, et al. Couples at risk: HIV-1 concordance and discordance among sexual partners receiving voluntary counseling and testing in Uganda. *J. AIDS* 2005; 39: 576–580. PMID: [16044010](#)
15. Guimaraes M, Castilho E, Ramos-Filho C. Heterosexual transmission of HIV-1: a multicenter study in Rio de Janeiro, Brazil [abstract]. VII th International Conference on AIDS 1991; MC3098.
16. Allen S, Lindan C, Serufilira A, Rundle AC, Nsengumuremyi F, Carael M, et al. Human immunodeficiency virus infection in urban Rwanda. Demographic and behavioral correlates in a representative sample of childbearing women. *JAMA* 1991; 266: 1657–63. PMID: [1886188](#)
17. Chao A, Bulterys M, Musanganire F, Habimana P, Nawrocki P, Taylor E, et al. Risk factors associated with prevalent HIV-1 infection among pregnant women in Rwanda—National University of Rwanda-Johns Hopkins University AIDS Research Team. *Int J Epidemiol* 1994; 23: 371–80. PMID: [8082965](#)
18. Gray R, Thoma R, Laeyendecker O, Serwadda D, Nalugoda F, Kigozi G, et al. Male Circumcision and the Risks of Female HIV and STI Acquisition in Rakai, Uganda. Presentation at the 2006 Conference on Retroviruses and Opportunistic Infections (CROI), Feb 8, Denver Colorado. Press. Available: www.hopkinsmedicine.org/Press_releases/2006/02_08_06.html. Accessed 28 February 2006.

19. Wawer MJ, Makumbi F, Kigozi G, Serwadda D, Watya S, Nalugoda F, et al. Circumcision in HIV infected men and its effect on HIV transmission to female partners in Rakai, Uganda: a randomised controlled trial. Lancet 2009; 374: 229–37. doi: [10.1016/S0140-6736\(09\)60998-3](https://doi.org/10.1016/S0140-6736(09)60998-3) PMID: [19616720](#)
20. Kapiga SH, Lyamuya EF, Lwihula GK, Hunter DJ. The incidence of HIV infection among women using family planning methods in Dar es Salaam, Tanzania. AIDS 1998; 12: 75–84. PMID: [9456257](#)
21. Turner AN, Morrison CS, Padian NS, Kaufman JS, Salata RA, Chipato T, et al. Men's circumcision status and women's risk of HIV acquisition in Zimbabwe and Uganda. AIDS 2007; 21: 1779–89. PMID: [17690577](#)
22. Baeten J, Donnell D, Inambao M, Ronald A, John-Stewart G, Inambao M, et al. Male circumcision and risk of male-to-female HIV-1 transmission: a multinational prospective study in African HIV-1-serodiscordant couples. AIDS 2010; 24: 737–744. doi: [10.1097/QAD.0b013e32833616e0](https://doi.org/10.1097/QAD.0b013e32833616e0) PMID: [20042848](#)
23. Higgins JPT, Altman DG (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins J, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration 2011. Available: www.cochrane-handbook.org.
24. Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration 2011. Available: www.cochrane-handbook.org.
25. Sterne JAC, Egger M, Moher D. (Editors). Chapter 10: Addressing reporting biases in Cochrane Handbook for Systematic Reviews of Interventions (eds. JPT Higgins and S Green). Version 5.1.0 [updated March 2011]. The Cochrane Collaboration 2011. Available: www.cochrane-handbook.org.
26. Weiss HA, Quigley MA, Hayes RJ. Male circumcision and risk of HIV infection in sub-Saharan Africa: a systematic review and meta-analysis. AIDS 2000; 14: 2361–70. PMID: [11089625](#)
27. McCoombes SG, Short RV. Potential HIV 1 target cens in the hu. nlan penis. AIDS, 2006, 20: 1491–1495. PMID: [16847403](#)
28. Patterson BK, Landay A, Siegel JN, Flener Z, Pessis D, Chaviano A, el al. Susceptibility to human immunodeficiency virus—I infection of human foreskin and cervical tissue grown in explant culture. Am J Pathol 2002; 161:867–873. PMID: [12213715](#)
29. Donoval BA, Landay AL, Moses S, Agot K, Ndirinya-Achola JO, Nyagaya EA, et al. HIV-1 target cells in foreskins of African men with varying histories of sexually transmitted infections. Am J Clin Pathol. 2006; 125: 386–91. PMID: [16613341](#)
30. Weiss HA, Hankins CA, Dickson K. Male circumcision and risk of HIV infection in women: a systematic review and meta-analysis. Lancet Infect Dis 2009; 9: 669–77. doi: [10.1016/S1473-3099\(09\)70235-X](https://doi.org/10.1016/S1473-3099(09)70235-X) PMID: [19850225](#)
31. Kigozi G, Gray RH, Wawer MJ, Serwadda D, Makumbi F, Watya S, et al. The safety of adult male circumcision in HIV-infected and uninfected men in Rakai Uganda. PLoS Med 2008; 5: e116. doi: [10.1371/journal.pmed.0050116](https://doi.org/10.1371/journal.pmed.0050116) PMID: [18532873](#)
32. Gray RH, Kigozi G, Serwadda D, Makumbi F, Nalugoda F, Watya S, et al. The effects of male circumcision on female partners' genital tract symptoms and vaginal infections in a randomized trial in Rakai, Uganda. Am J Obstet Gynecol 2009; 200: e1–e7.
33. Wawer MJ, Kigozi G, Serwadda D. Trial of male circumcision in HIV positive men: effects in men and women[Abstract]. 15th Conference on Retroviruses and Opportunistic Infections 2008; 33LB.
34. Sobngwi-Tambekou J, Taljaard D, Lissouba P, Lissouba P, Zarca K, Puren A, et al. Effect of HSV-2 serostatus on acquisition of HIV by young men: results of a longitudinal study in Orange Farm, South Africa. J Infect Dis 2009; 199: 958–64. doi: [10.1086/597208](https://doi.org/10.1086/597208) PMID: [19220143](#)
35. Tobian AA, Serwadda D, Quinn TC, Kigozi G, Gravitt PE, Laeyendecker O, et al. Male circumcision for the prevention of HSV-2 and HPV infections and syphilis. N Engl J Med 2009; 360: 1298–309. doi: [10.1056/NEJMoa0802556](https://doi.org/10.1056/NEJMoa0802556) PMID: [19321868](#)
36. Auvert B, Sobngwi-Tambekou J, Cutler E, Nieuwoudt M, Lissouba P, Puren A, et al. Effect of male circumcision on the prevalence of high-risk human papilloma virus in young men: results of a randomised controlled trial conducted in Orange Farm, South Africa. J Infect Dis 2009; 199: 14–19. doi: [10.1086/595566](https://doi.org/10.1086/595566) PMID: [19086814](#)
37. World Health Organisation (WHO). New data on male circumcision and HIV prevention: policy and programme implications. Montreux 2007. Available: http://libdoc.who.int/publications/2007/9789241595988_eng.pdf?uca=1
38. World Health Organisation (WHO). Information package on male circumcision and HIV prevention. Geneva 2007. Available: <http://www.who.int/hiv/pub/malecircumcision/infopack/en/>